Nonetheless it is clear that routinely assessing AR status at the time of diagnosis for breast cancer should be encouraged that will allow the AR status along with ERα/PR and HER2 status to be used for selecting therapeutic treatment for breast cancer. The gene discussed is AR; the disease is breast carcinoma.